Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer.
An increasing number of studies provide evidences linking disruption of Fanconi anemia/BRCA cascade with sporadic cancers. Given that this pathway plays essential roles in response to the DNA interstrand cross-links, these cancers are expected to be chemosensitive to cross-link based therapy. In the present mini-review we expand the spectrum of possibilities for FA/BRCA disruption and review some works describing functional upstream and downstream events linking disruption of the FA/BRCA pathway to sporadic cancer. This may involve but not limited to epigenetic silencing of the FA-core complex or BRCA1/2, mutations of one or several FA-BRCA genes or modification of encoded products. All this may serve as a platform for occurrence, development and treatment of sporadic cancers and therefore deserves to be in the focus of new research directions.
Lyakhovich
Alex
A
Group of Mutagenesis, Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
Surralles
Jordi
J
D002869:Chromosome Aberrations; D052219:Fanconi Anemia Complementation Group F Protein / Q000235:genetics*; D020868:Gene Silencing; D019398:Genes, BRCA1; D006801:Humans; D009369:Neoplasms / Q000235:genetics*; D015398:Signal Transduction
C499901:FANCF protein, human; D052219:Fanconi Anemia Complementation Group F Protein